The authors would like to thank InSight Ltd., Rehovot, Israel for providing them with the anti-heparanase antibody and heparanase cDNA used in the study.
The mentioned reagents are proprietary of InSight.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/sj.bjc.6600232
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Rohloff, J., Zinke, J., Schoppmeyer, K. et al. Erratum: Heparanase is a prognostic indicator for postoperative survival in pancreatic carcinoma. Br J Cancer 87, 689 (2002). https://doi.org/10.1038/sj.bjc.6600504
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600504
